Replies to post #66692 on Biotech Values

[DewDiligence]

>MNTA – Do you make any reason why the 8-K route - no PR afterwards?<

They probably didn’t think it warranted a PR because they had already told investors on several occasions that the response would be submitted by the end of the month.

>And why Sandoz on the 8-K…?<

The Lovenox ANDA is in Sandoz’s name.